about
Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune TherapyAutomated cell tracking and analysis in phase-contrast videos (iTrack4U): development of Java software based on combined mean-shift processesTargeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genesEZH2 as a mediator of treatment resistance in melanomap16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumorsSomatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in MelanomaHistone deacetylases (HDACs) as mediators of resistance to apoptosis in melanoma and as targets for combination therapy with selective BRAF inhibitors.Intralesional immunotherapy for melanoma.EZH2: an emerging role in melanoma biology and strategies for targeted therapy.Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151.The epigenetic regulator I-BET151 induces BIM-dependent apoptosis and cell cycle arrest of human melanoma cells.Epigenetic modulation in cancer immunotherapy.A focus on PD-L1 in human melanoma.HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma.Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report.General strategy to analyse coat colour phenotypes in mice.General strategy to analyse melanoma in mice.Simulation of melanoblast displacements reveals new features of developmental migration.SIRT6 haploinsufficiency induces BRAF melanoma cell resistance to MAPK inhibitors via IGF signallingHow anti-PD1 treatments are changing the management of melanoma.The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistanceCo-targeting BET proteins and MCL1 induces synergistic cell death in melanomaMarked Global DNA Hypomethylation Is Associated with Constitutive PD-L1 Expression in MelanomaTargeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy
P50
Q26783032-D761F1BB-D72D-4094-A815-5675A496C659Q27301323-9CE080E2-B534-4613-B851-21363B30C9F3Q27853201-BBCEA5E7-A58C-4F85-8BEB-B94A7FE2CABDQ28074492-33D6007A-041F-4D50-AB59-B790ECB33A50Q36944185-F9393181-DD7E-440C-B5CD-B3C9FD9E99B3Q37218158-0358DC5A-DB25-43F3-9DD3-90F83F432086Q38041721-EE6D4596-1E2B-47AA-A6E5-8AED2FDC5A6FQ38168460-93733C2A-B643-496F-B9EB-1AA9DF6C6CB7Q38218836-3FA99A0A-DA80-4F33-ACCF-7BAF6C2437ADQ38985389-8300E2DB-7127-4EF1-BA0F-AC594C2F9C39Q38987491-FE1C1F88-E0D1-4606-8FB0-2281203A4889Q39369845-66538EBA-F273-4EB2-8EE9-12B7C254019DQ46927027-42603293-106C-407F-9E10-2F55153C4B11Q47325071-B58C64BE-2084-4534-9CA1-400E0E2DF288Q49383236-A826711D-4F2D-4993-8FF4-9C37CAEB0455Q51847405-69238A1D-7A56-4C3F-9B31-9B6E48EEDED9Q51852441-428BB7DE-E437-4AE0-92FB-74C88181C874Q55716926-E933094F-A15F-41DB-8BC9-7AFCF225C708Q57010854-746ACF2B-A54C-4BB7-A1B3-FF34FFF2E761Q64978186-AAA5B8C6-B1AD-47E1-BB93-CC4777241685Q85244961-71C84F8B-7C74-44E9-83BD-BA1038B60EE9Q91580542-3BC9F1B3-0D91-4DA9-B7E7-724977142B02Q91626737-B0673F6A-93A2-414A-AF81-31780DF29A85Q92252021-4919BE59-13A9-4220-85DC-5E8BC236F8F6
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Stuart J Gallagher
@nl
Stuart J Gallagher
@sl
Stuart J. Gallagher
@en
Stuart J. Gallagher
@es
type
label
Stuart J Gallagher
@nl
Stuart J Gallagher
@sl
Stuart J. Gallagher
@en
Stuart J. Gallagher
@es
altLabel
Stuart J Gallagher
@en
prefLabel
Stuart J Gallagher
@nl
Stuart J Gallagher
@sl
Stuart J. Gallagher
@en
Stuart J. Gallagher
@es
P1053
E-6617-2011
P106
P1153
8924498200
P31
P3829
P496
0000-0003-2651-9671